You are here

Home » Content

Hemodiyaliz hastalarında rekombinan hepatit B aşısının antikor cevabına etki eden faktörler

The factors affect the antibody answer to recombinant hepatitis B vaccine in hemodialysis

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
22 male. 14 female hemodialysis patients (HP) were included in this study. 20 microgram recombinant Hepatit B vaccine were given at 0, 1st and 6th months in deltoid muscle. The level of anli-HBs. C3. ('4. Total lg(i were performed by EL1SA. Total lymphocytes count were performed by Techinon HI H~3. '14, 7 <V lymphocytes and T4:TH ratio were measured by I FA. Data were analysed by mini tab computer programme. The level of anti-HBs were protective 69.04 percent of patients. There was a significant correlation between age. T4 lymphocyte, level of serum crcatinin and ant i HBs levels (p 0.05. But there was no correlation between weight, sex, anti-HCl' antibody positivity. duration of dialysis, abnormal liver functions, C3. C4, TH lymphocytes. T4:TH ratio and immun response to hepatitis B vaccination in HI'. /Journal of Turgut Özal Medical Center l(4):263-26~./994J
Bookmark/Search this post with
Abstract (Original Language): 
Selçuk Üniversitesi Tıp Fakültesi Hemodiyaliz ( 'nitesinde düzenli olarak diyaliz programına bağlı 22 erkek. 14 kadın araştırmaya dahil edildi. Hartalara 0. 1 ve 6.ncı aylarda 20 microgram rekombinant hepatit B aşısı intramusküler olarak deltoid kasına yapıldı. Anti-HBs, C3. C4 ve total IgCi düzeyleri ölçüldü. T4 ve TH sayısı immun floresans yöntemi (İFA) ile sayıldı. Elde edilen sonuçlar mini tab istatistik programı ile bilgisayarda değerlendirildi. Hastaların % 69.04'ünde antikor düzeyi koruyucu düzeyde idi. Hepatit B aşının antikor cevabı ile T4 lenfosit, yaş ve serum kreatinin seviyesi arasında istatistiki olarak pozitif korelasyon bulundu (r 0.05. p 0.05). C3. C4, total lenfosit, TX lenfosit. T4. TS oranı, diyaliz süresi, ağırlık, cinsiyet. anti-lU I' pozitifliği, karaciğer fonksiyon testleri arasında istatistiki olarak anlamlı bir korelasyon yoktu. /Turgut Özal Tıp Merkezi Dergisi 1(4)':263-267,1994/
FULL TEXT (PDF): 
PDF icon arastirmax-hemodiyaliz-hastalarinda-rekombinan-hepatit-b-asisinin-antikor-cevabina-etki-eden-faktorler.pdf
  • 4
263-267
  • Turkish

REFERENCES

References: 

1.Yalçındağ Ş. Aşı Bilgisi. Cerrahpaşa Tıp Fakültesi Yayınevi. İstanbul 1988;37-43.
2. FujiyamaS, Yoshida K, Sato T, ShinıadaH,Deguchi T
Immunogenicity and safety of recombinant yeast derived hepatitis B vaccine in hemodialysis patients. Hepatogastroenterology 1000; 37(suppl 2): 140-4.
3 Burugera M, Rodico JL, Alcazar JM, Oliver A Effect of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitits B vaccine in HP. Vaccine 1990; (8 suppl):S47-9
4 Crosnier J. Hepatitis B in hemodialysis: vaccination against HBs antigen. Proc Eur Dial Transplant Assoc 1981;18:231-40.
5 Horak W, Leither C, Kemenesi W, Pinggera W. Efficiacy and tolerance of hepatitis B vaccination on medical personel and hemodialysis patients. Wien Klin Wochenschr 1984; 17;96{4): 161-5.
6 Tetta C, Fidelio T, Licata C. Production of TNF alpha in patients on hemodiofiltration. Nephron 1992;61(2): 135-8.
6. Urena P, Herbelin A, Zingraf J. Permeability of sellulosic and non-sellulosic membranes to endotoxin subunits and cytokine production during in vitro hemodialysis. Nephron Dial Transplant 1992; 7( 1): 16-28.
7. Hoi linger BF. Factors influencing the immune response hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med 1989;87(3):36-40.
8 Leijs S. Kramer P, Heijtink RA, Hop WC, Schalm SW. Hepatitis B vaccination of hemodialysis patients. Eur Clin Invest 1990;20(5): 540-5.
9 Burugera M, Cramades M, Mayor A, Sanchez
JM, Rodes J lmmunogenecity of a recombinant hepatitis B vaccine in HP Postgard Med J 1987.(63 suppl 2): 155-8
10 De-greaff PA. Dankert J, De Zeeuw D. Gips CH. Van-Der-Hem-GK. Immune response to two different hepatitis B vaccines in hemodialysis patients. Nephron. 1985; 40(2): 155-60
11. Laurence J. T-Cell subsets in health, infectious disease, and idiopathic T4 T lymphocytopenia. Ann Intern Med 1993.119:55-62.
12 Raska K, Raskova J, Shea SM, Frankel RM T cell subsets and cellular immunity in end stage renal disease Am J Med 1983;75(5): 734-40.
13 Senneseal JJ, Nippen P, Verbellen DL, Verbellen DL. Treatment with recombinant human erythropoietin inceases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991 ;40( 1): 121-8.
14. Denis F, Mounier M, Hessel L. Hepatitis B vaccination in elderly. J Infect Dis 1984; 149: 1019.
15 BatoreIli P, Burunetto MR, Minutello MA. T lymphocypte response to HCV in different clinical courses of infection. Gastroenterology 1993; 104: 580-7.
16. Plasman GS, Heinz G, Wagner G, Derfler K. T-cell selection ant T-cell receptor variable beta chain usage in chronic hemodialysis patients. Clin Nephrology 1992;37(5):252-9.
17. Kıhçturgay K. Viral Hepatit 92. Tayf Ofset. Istanbul 1992:9.
18.
Kıhçturga
y K. İmmünolojiye Giriş. Tayf Ofset. Bursa 1994:54.

Thank you for copying data from http://www.arastirmax.com